Hansoh Pharmaceutical Group Company Limited
翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3692)

VOLUNTARY ANNOUNCEMENT
REGAINING OF THE RESEARCH, DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION RIGHTS TO ALMONERTINIB OUTSIDE OF THE PRC

The board of directors (the "**Board**") of Hansoh Pharmaceutical Group Company Limited (the "**Company**" and together with its subsidiaries, the "**Group**") announces that the Group received a written notice from EQRx, Inc. ("**EQRx**") in relation to the termination of the strategic collaboration and license agreement entered into between EQRx and the Group's subsidiaries, Hansoh (Shanghai) Healthtech Company Limited* (翰森(上海)健康科技有限公司) and Jiangsu Hansoh Pharmaceutical Group Company Limited* (江蘇豪森藥業集團有限公司) (the "**Subsidiaries**") on July 23, 2020 (the "**License Agreement**") in relation to aumolertinib. The License Agreement will be terminated upon the expiry of the term as stipulated therein. The Group will regain the research, development, manufacture and commercialization rights to aumolertinib outside of the People's Republic of China ("**PRC**") upon the termination of the License Agreement. The termination of the License Agreement will not affect the upfront payment and milestone payments previously received by the Group from EQRx. The parties will discuss on any transition activities.

The marketing authorization applications (the "**MAAs**") with the Medicines and Healthcare Products Regulatory Agency (the "**MHRA**") in the United Kingdom and the European Medicines Agency (the "**EMA**") for aumolertinib as a first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer ("**NSCLC**") with sensitizing EGFR mutations and for the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC are under review. Upon completion of the transition, the Group will lead the regulatory review process for aumolertinib MAAs by the MHRA and the EMA.

As disclosed in the announcement of the Company dated on July 23, 2020, the Subsidiaries entered into the License Agreement with EQRx. Pursuant to the License Agreement, the Subsidiaries have granted an exclusive license to permit EQRx to research, develop, manufacture and commercialize aumolertinib and any product containing or comprising of aumolertinib outside of the PRC.

The Board is of the view that the termination of the License Agreement will not have any material impact on the business operations or financial position of the Group.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, August 4, 2023

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Ms. Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.

* *For identification purposes only*